VGLL3
Transcription cofactor vestigial-like protein 3
Also known as: VGL-3, VGLL3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A8MV65
- Gene
- VGLL3
- Ensembl
- ENSG00000206538
- Chromosome
- 3
- Canonical length
- 326 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoli,Cytosol
OverviewNCBI Gene
Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
326 residues, UniProt reviewed canonical sequence.
>A8MV65|VGLL3
1 MSCAEVMYHP QPYGASQYLP NPMAATTCPT AYYQPAPQPG QQKKLAVFSK MQDSLEVTLP
61 SKQEEEDEEE EEEEKDQPAE MEYLNSRCVL FTYFQGDIGS VVDEHFSRAL GQAITLHPES
121 AISKSKMGLT PLWRDSSALS SQRNSFPTSF WTSSYQPPPA PCLGGVHPDF QVTGPPGTFS
181 AADPSPWPGH NLHQTGPAPP PAVSESWPYP LTSQVSPSYS HMHDVYMRHH HPHAHMHHRH
241 RHHHHHHHPP AGSALDPSYG PLLMPSVHAA RIPAPQCDIT KTEPTTVTSA TSAWAGAFHG
301 TVDIVPSVGF DTGLQHQDKS KESPWYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against VGLL3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.69
- Highest tissue expression
- 38 nTPM
Expression across tissuesHPA
Tissue
- placenta: 38 nTPM
- adipose tissue: 20 nTPM
- lung: 15 nTPM
- blood vessel: 13 nTPM
- ovary: 11 nTPM
- prostate: 10 nTPM
Single-cell type
- extravillous trophoblasts: 490 nCPM
- urothelial cells: 298 nCPM
- leydig cells: 269 nCPM
- syncytiotrophoblasts: 262 nCPM
- peritubular myoid cells: 254 nCPM
- early spermatids: 235 nCPM
Immune cell
- basophil: 0.4 nTPM
- neutrophil: 0.2 nTPM
- eosinophil: 0.1 nTPM
- naive B-cell: 0.1 nTPM
- NK-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
Brain region
- hypothalamus: 17 nTPM
- choroid plexus: 17 nTPM
- amygdala: 14 nTPM
- cerebral cortex: 8.9 nTPM
- thalamus: 7.8 nTPM
- midbrain: 7.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.75
- gnomAD pLI
- 0.07
- gnomAD missense Z
- 0.22
- DepMap mean gene effect
- -0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VGLL3 as an antibody target. Whether an autoantibody or antibody against VGLL3 could matter depends on whether native VGLL3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VGLL3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label VGLL3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...